Hospital
The Good Samaritan Hospital of Cincinnati, Ohio
The Good Samaritan Hospital of Cincinnati, Ohio was paid $85.63M by Medicaid between Jan 2018 and Dec 2024, across 482 billing codes. Its largest line is 99283, emergency room visit (moderate) — 14% of everything it billed.
33Billing provider infoTHE GOOD SAMARITAN HOSPITAL OF CINCINNATI, OHIO
CINCINNATI, OH 45220
CINCINNATI, OH 45220
33aNPI1508835828assigned 03/17/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$85.63M
24GClaims1,959,903
24DCodes billed482
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Ohio
Rank by total paid#12 of 101
Median peer was paid$22.32M
This provider vs. median3.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 170,045 | $5.62M | |
| 2019 | 159,988 | $5.45M | |
| 2020 | 144,006 | $7.09M | |
| 2021 | 174,908 | $7.97M | |
| 2022 | 186,326 | $8.22M | |
| 2023 | 639,545 | $30.01M | |
| 2024incomplete | 485,085 | $21.27M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 97,541 | 89,683 | $11.90M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 70,540 | 63,058 | $10.00M |
| 96361 | Intravenous infusion, hydration; each additional hour | 9.6% | 27,133 | 21,322 | $8.24M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 9.5% | 72,325 | 54,456 | $8.16M |
| J9271 | Injection, pembrolizumab, 1 mg | 8.0% | 861 | 569 | $6.83M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 6.1% | 42,849 | 33,293 | $5.24M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 4.0% | 16,773 | 8,530 | $3.43M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.1% | 14,464 | 12,385 | $1.79M |
| 59025 | Fetal non-stress test | 1.9% | 9,995 | 6,162 | $1.59M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.8% | 11,884 | 9,541 | $1.54M |
| J9173 | Injection, durvalumab, 10 mg | 1.7% | 514 | 88 | $1.49M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.6% | 5,734 | 4,572 | $1.37M |
470 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.5% | 5,689 | $1.32M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.1% | 7,298 | $944K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,097 | $813K |
| J9299 | Injection, nivolumab, 1 mg | <1% | 208 | $778K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,102 | $732K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 6,197 | $658K |
| G0378 | Hospital observation service, per hour | <1% | 8,254 | $622K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 4,574 | $594K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 4,685 | $557K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,971 | $537K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,921 | $531K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,938 | $485K |
| J1459 | Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | <1% | 340 | $469K |
| 64483 | <1% | 722 | $419K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 8,809 | $408K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,634 | $393K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 3,301 | $389K |
| 96415 | <1% | 1,472 | $380K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 928 | $370K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 649 | $345K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 3,292 | $344K |
| 80047 | <1% | 18,309 | $331K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 613 | $321K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 4,470 | $319K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 10,113 | $302K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,567 | $296K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,991 | $285K |
| 76818 | <1% | 2,657 | $280K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 200 | $258K |
| 86850 | <1% | 12,012 | $250K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 250 | $233K |
| 11043 | <1% | 933 | $233K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 323 | $232K |
| 96367 | <1% | 2,332 | $208K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 960 | $206K |
| 80053 | Comprehensive metabolic panel | <1% | 31,013 | $180K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 72,723 | $172K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 620 | $160K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 136,188 | $159K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,043 | $156K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 47,045 | $153K |
| 70496 | <1% | 845 | $151K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 18,371 | $146K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 802 | $142K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 10,666 | $135K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 4,165 | $134K |
| 86900 | <1% | 12,258 | $131K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,274 | $131K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 291 | $129K |
| 10060 | <1% | 706 | $114K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 145 | $111K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 761 | $105K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 663 | $103K |
| 76801 | <1% | 744 | $100K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 148,906 | $98K |
| 80076 | <1% | 32,360 | $95K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,037 | $94K |
| 76642 | <1% | 848 | $94K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 930 | $93K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,883 | $93K |
| 19318 | <1% | 22 | $92K | |
| 84484 | <1% | 21,153 | $91K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 23,423 | $89K |
| 71271 | <1% | 528 | $87K | |
| 94060 | <1% | 690 | $86K | |
| 70491 | <1% | 325 | $83K | |
| 43235 | <1% | 176 | $80K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 642 | $79K |
| 71045 | Radiologic examination, chest; single view | <1% | 23,883 | $77K |
| 71250 | <1% | 816 | $77K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 35,727 | $74K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 504 | $74K |
| 76820 | <1% | 1,128 | $72K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,786 | $72K |
| 93971 | <1% | 886 | $71K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,929 | $71K |
| 90677 | <1% | 445 | $70K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,059 | $63K |
| 82607 | <1% | 5,783 | $63K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,830 | $61K |
| 36430 | <1% | 344 | $61K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 640 | $60K |
| 70498 | <1% | 986 | $59K | |
| 80061 | Lipid panel | <1% | 8,656 | $57K |
| 93017 | <1% | 640 | $56K | |
| 83970 | <1% | 2,190 | $54K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 478 | $51K |
| 93970 | <1% | 335 | $50K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 297 | $49K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 11,462 | $47K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 37,109 | $47K |
| 86780 | <1% | 5,817 | $46K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 443 | $45K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 18,445 | $44K |
| 72141 | <1% | 299 | $44K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 233 | $44K |
| 85027 | <1% | 15,984 | $43K | |
| 94727 | <1% | 691 | $43K | |
| 88307 | <1% | 557 | $42K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 617 | $40K |
| 90715 | <1% | 2,682 | $39K | |
| 76536 | <1% | 371 | $39K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 23,263 | $38K |
| 97163 | <1% | 1,071 | $38K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 616 | $38K |
| 70486 | <1% | 563 | $38K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,343 | $37K |
| 12001 | <1% | 265 | $37K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 181 | $37K |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | <1% | 63 | $37K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 870 | $37K |
| 82728 | <1% | 7,256 | $37K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 282 | $36K |
| 84702 | <1% | 3,671 | $36K | |
| 94729 | <1% | 690 | $36K | |
| 97116 | <1% | 1,641 | $36K | |
| 86901 | <1% | 12,250 | $36K | |
| 72100 | <1% | 2,358 | $36K | |
| 90686 | <1% | 2,051 | $36K | |
| 97162 | <1% | 886 | $35K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 233 | $35K |
| 83735 | <1% | 13,760 | $32K | |
| 77386 | <1% | 151 | $32K | |
| 81025 | <1% | 53,451 | $31K | |
| 83540 | <1% | 8,173 | $30K | |
| 76830 | Ultrasound, transvaginal | <1% | 785 | $29K |
| 80320 | <1% | 2,749 | $28K | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 3,580 | $28K |
| 96416 | <1% | 532 | $27K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 7,159 | $27K |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | <1% | 314 | $27K |
| 77336 | <1% | 224 | $25K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,470 | $24K |
| 97167 | <1% | 692 | $23K | |
| 80069 | <1% | 1,745 | $23K | |
| 86762 | <1% | 4,057 | $23K | |
| 82525 | <1% | 1,536 | $21K | |
| 81001 | <1% | 43,734 | $21K | |
| 82746 | <1% | 3,283 | $20K | |
| 11045 | <1% | 74 | $20K | |
| 73560 | <1% | 1,955 | $19K | |
| 77334 | <1% | 62 | $19K | |
| 73630 | <1% | 1,942 | $19K | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 38 | $18K |
| 84439 | <1% | 1,553 | $18K | |
| 73030 | <1% | 1,705 | $18K | |
| 12002 | <1% | 126 | $18K | |
| 96523 | <1% | 416 | $17K | |
| S9470 | Nutritional counseling, dietitian visit | <1% | 189 | $17K |
| 96376 | <1% | 4,793 | $16K | |
| 83550 | <1% | 6,636 | $16K | |
| 72040 | <1% | 1,005 | $16K | |
| 81002 | <1% | 33,812 | $16K | |
| 74183 | <1% | 72 | $16K | |
| 76775 | <1% | 177 | $16K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 3,195 | $15K |
| 87510 | <1% | 537 | $15K | |
| 77062 | <1% | 405 | $15K | |
| 82570 | <1% | 3,779 | $15K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 975 | $15K |
| 73130 | <1% | 1,446 | $15K | |
| 84425 | <1% | 1,523 | $15K | |
| 73610 | <1% | 1,503 | $15K | |
| 12011 | <1% | 92 | $14K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 13,492 | $14K |
| 74018 | <1% | 506 | $14K | |
| 83880 | <1% | 4,440 | $13K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 768 | $13K |
| 84630 | <1% | 1,532 | $13K | |
| 86140 | <1% | 2,961 | $13K | |
| 88185 | <1% | 197 | $13K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 9,017 | $12K |
| 96368 | <1% | 1,041 | $12K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 644 | $12K |
| 87340 | <1% | 1,634 | $12K | |
| 93325 | <1% | 131 | $11K | |
| 85610 | <1% | 6,201 | $11K | |
| 93880 | <1% | 163 | $11K | |
| 62323 | <1% | 30 | $11K | |
| J3490 | Unclassified drugs | <1% | 6,666 | $11K |
| 84590 | <1% | 1,431 | $11K | |
| J2997 | Injection, alteplase recombinant, 1 mg | <1% | 91 | $11K |
| 77300 | <1% | 22 | $11K | |
| 20610 | <1% | 88 | $11K | |
| 64493 | <1% | 21 | $10K | |
| 36591 | <1% | 480 | $10K | |
| 84144 | <1% | 500 | $10K | |
| 82951 | <1% | 457 | $10K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,328 | $10K |
| 82565 | <1% | 3,147 | $10K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,519 | $10K |
| 82962 | <1% | 9,238 | $9K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 740 | $9K |
| 86481 | <1% | 490 | $9K | |
| 95816 | <1% | 49 | $9K | |
| 93976 | <1% | 77 | $9K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 24 | $9K |
| 73502 | <1% | 921 | $9K | |
| 83690 | <1% | 22,855 | $9K | |
| 72070 | <1% | 531 | $9K | |
| 87522 | Neg quan hep c or qual rna | <1% | 468 | $9K |
| 87653 | <1% | 849 | $8K | |
| 77080 | <1% | 123 | $8K | |
| 77065 | Tomosynthesis, mammo | <1% | 397 | $8K |
| 36593 | <1% | 90 | $8K | |
| 73110 | <1% | 922 | $8K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,904 | $8K |
| 87660 | <1% | 551 | $8K | |
| 82950 | <1% | 2,841 | $8K | |
| 97802 | <1% | 88 | $8K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,968 | $8K |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 6,958 | $7K |
| 88341 | <1% | 148 | $7K | |
| 95811 | <1% | 13 | $7K | |
| J2791 | Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu | <1% | 104 | $6K |
| J1726 | Injection, hydroxyprogesterone caproate, (makena), 10 mg | <1% | 13 | $6K |
| 77066 | Tomosynthesis, mammo | <1% | 468 | $6K |
| 97166 | <1% | 156 | $6K | |
| 82952 | <1% | 455 | $6K | |
| 91322 | <1% | 226 | $6K | |
| 84156 | <1% | 3,116 | $6K | |
| 73562 | <1% | 467 | $6K | |
| 81003 | <1% | 17,994 | $6K | |
| 72131 | <1% | 69 | $5K | |
| 84100 | <1% | 1,860 | $5K | |
| 88184 | <1% | 137 | $5K | |
| 97014 | <1% | 197 | $5K | |
| 80349 | <1% | 299 | $5K | |
| 86038 | <1% | 426 | $5K | |
| 93925 | <1% | 40 | $5K | |
| 87210 | <1% | 6,503 | $5K | |
| 84550 | <1% | 3,351 | $5K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 74 | $5K |
| 84153 | <1% | 781 | $5K | |
| 83615 | <1% | 4,265 | $5K | |
| 71100 | <1% | 494 | $5K | |
| 92558 | <1% | 86 | $4K | |
| 83605 | <1% | 4,123 | $4K | |
| 82784 | <1% | 1,279 | $4K | |
| 73070 | <1% | 563 | $4K | |
| 73140 | <1% | 401 | $4K | |
| 73221 | <1% | 17 | $4K | |
| 77061 | <1% | 129 | $4K | |
| 85652 | <1% | 1,699 | $4K | |
| 80348 | <1% | 205 | $4K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 634 | $4K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 12,011 | $4K |
| 82533 | <1% | 239 | $4K | |
| 82247 | <1% | 2,373 | $4K | |
| 83883 | <1% | 1,003 | $4K | |
| 82043 | <1% | 1,255 | $4K | |
| 83020 | <1% | 346 | $4K | |
| G0008 | Administration of influenza virus vaccine | <1% | 2,288 | $3K |
| 82664 | <1% | 308 | $3K | |
| 87040 | <1% | 2,076 | $3K | |
| 90656 | <1% | 395 | $3K | |
| 87077 | <1% | 2,968 | $3K | |
| 83516 | <1% | 335 | $3K | |
| 82550 | <1% | 996 | $3K | |
| 87070 | <1% | 2,889 | $3K | |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 246 | $3K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 148 | $3K |
| 72110 | <1% | 61 | $3K | |
| 86431 | <1% | 289 | $3K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,217 | $3K |
| 86923 | <1% | 101 | $3K | |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 1,053 | $3K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 17,244 | $3K |
| 84450 | <1% | 2,479 | $3K | |
| 90480 | <1% | 224 | $3K | |
| 84460 | <1% | 2,469 | $3K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 15 | $3K |
| 29515 | <1% | 609 | $3K | |
| 73590 | <1% | 388 | $3K | |
| 80074 | <1% | 367 | $3K | |
| 87186 | <1% | 2,745 | $3K | |
| 83001 | <1% | 164 | $3K | |
| 85730 | <1% | 4,007 | $2K | |
| 88342 | <1% | 653 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 30,172 | $2K |
| 85045 | <1% | 2,091 | $2K | |
| 73700 | <1% | 33 | $2K | |
| 86706 | <1% | 269 | $2K | |
| 84165 | <1% | 672 | $2K | |
| 97597 | <1% | 20 | $2K | |
| 96402 | <1% | 303 | $2K | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 4,574 | $2K |
| 84520 | <1% | 1,834 | $2K | |
| 29125 | <1% | 415 | $2K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,303 | $2K |
| 87536 | <1% | 123 | $2K | |
| 90837 | Psychotherapy session, about an hour | <1% | 18 | $2K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 15 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,786 | $2K |
| 85379 | <1% | 1,957 | $2K | |
| 97803 | <1% | 18 | $2K | |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 238 | $2K |
| 83525 | <1% | 73 | $2K | |
| 84403 | <1% | 143 | $2K | |
| 74019 | <1% | 164 | $2K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 108 | $2K |
| 84145 | <1% | 708 | $1K | |
| 82803 | <1% | 1,923 | $1K | |
| 84146 | <1% | 101 | $1K | |
| 93225 | <1% | 15 | $1K | |
| 88304 | <1% | 615 | $1K | |
| 00840 | <1% | 114 | $1K | |
| 88360 | <1% | 17 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 14,983 | $1K |
| 86304 | <1% | 252 | $1K | |
| 86870 | <1% | 49 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,905 | $1K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 6,877 | $1K |
| 97161 | <1% | 60 | $1K | |
| 87480 | <1% | 537 | $1K | |
| 87430 | <1% | 2,328 | $987.61 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,486 | $966.54 |
| 87205 | <1% | 950 | $954.35 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,454 | $953.52 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,219 | $938.73 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 858 | $928.45 |
| J2704 | Injection, propofol, 10 mg | <1% | 9,934 | $925.08 |
| 86200 | <1% | 104 | $921.63 | |
| 87088 | <1% | 931 | $910.51 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 30 | $899.25 |
| 73090 | <1% | 118 | $847.87 | |
| 93242 | <1% | 14 | $839.35 | |
| 86920 | <1% | 25 | $808.93 | |
| 87493 | <1% | 32 | $796.24 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,746 | $792.72 |
| 85018 | <1% | 329 | $783.56 | |
| Q0114 | Fern test | <1% | 744 | $778.59 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,757 | $770.49 |
| 82105 | <1% | 96 | $738.25 | |
| 76937 | <1% | 19 | $717.00 | |
| 92523 | <1% | 12 | $709.94 | |
| 80358 | <1% | 72 | $693.11 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,890 | $686.23 |
| 92567 | <1% | 112 | $683.81 | |
| 80306 | <1% | 358 | $668.85 | |
| 82378 | <1% | 402 | $651.45 | |
| 86704 | <1% | 81 | $641.02 | |
| 85014 | <1% | 399 | $600.81 | |
| 86235 | <1% | 61 | $579.21 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 92 | $535.40 |
| 82627 | <1% | 14 | $508.47 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 207 | $506.57 |
| 86361 | <1% | 59 | $499.55 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 629 | $492.27 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 75 | $491.91 |
| 84402 | <1% | 30 | $488.44 | |
| 92582 | <1% | 16 | $476.26 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 616 | $440.88 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 1,108 | $438.43 |
| 83010 | <1% | 218 | $416.36 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 3,369 | $415.95 |
| 82010 | <1% | 721 | $414.45 | |
| 86160 | <1% | 71 | $387.57 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,528 | $381.42 |
| 87481 | <1% | 45 | $379.54 | |
| 82947 | <1% | 58 | $367.02 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,522 | $359.22 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,404 | $347.34 |
| 86161 | <1% | 40 | $345.45 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 58 | $339.72 |
| G0009 | Administration of pneumococcal vaccine | <1% | 449 | $317.19 |
| 97750 | <1% | 13 | $293.42 | |
| 90678 | <1% | 55 | $288.35 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,784 | $278.38 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 885 | $277.71 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,964 | $276.44 |
| 82670 | <1% | 25 | $275.85 | |
| 86593 | <1% | 161 | $272.54 | |
| 82140 | <1% | 149 | $270.12 | |
| 84703 | <1% | 149 | $267.59 | |
| 80329 | <1% | 220 | $267.10 | |
| 82150 | <1% | 245 | $262.62 | |
| 88720 | <1% | 29 | $256.99 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 260 | $250.93 |
| 84270 | <1% | 14 | $230.26 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 45 | $229.80 |
| 36416 | <1% | 1,101 | $227.61 | |
| 0124A | <1% | 61 | $225.96 | |
| 86698 | <1% | 46 | $215.85 | |
| J1815 | Injection, insulin, per 5 units | <1% | 670 | $210.10 |
| 29240 | <1% | 16 | $198.73 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,152 | $195.60 |
| 82985 | <1% | 52 | $186.74 | |
| 86225 | <1% | 32 | $173.82 | |
| 87015 | <1% | 124 | $172.44 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,458 | $168.80 |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 197 | $167.87 |
| 86364 | <1% | 12 | $163.04 | |
| 83921 | <1% | 86 | $151.86 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,892 | $149.33 |
| 86376 | <1% | 12 | $141.62 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,292 | $134.21 |
| 83090 | <1% | 45 | $133.25 | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 2,174 | $132.74 |
| 84132 | <1% | 53 | $132.45 | |
| 86147 | <1% | 14 | $130.45 | |
| 85612 | <1% | 28 | $128.27 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 705 | $120.15 |
| C1769 | Guide wire | <1% | 317 | $118.25 |
| 86301 | <1% | 18 | $111.04 | |
| 82272 | <1% | 226 | $107.37 | |
| 72220 | <1% | 17 | $105.50 | |
| 90750 | <1% | 23 | $101.79 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 781 | $100.20 |
| 86146 | <1% | 14 | $98.67 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,138 | $95.72 |
| 80143 | <1% | 322 | $95.03 | |
| 82248 | <1% | 36 | $94.11 | |
| 84481 | <1% | 12 | $92.62 | |
| 87081 | <1% | 90 | $91.47 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,628 | $85.17 |
| 81050 | <1% | 17 | $84.60 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,891 | $72.66 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 717 | $72.10 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,861 | $60.90 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 525 | $58.76 |
| 90662 | <1% | 17 | $57.24 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 294 | $55.03 |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | <1% | 743 | $54.41 |
| 87075 | <1% | 114 | $46.49 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 105 | $40.50 |
| 80164 | <1% | 14 | $33.92 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 72 | $31.91 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 22 | $27.66 |
| 94760 | <1% | 1,219 | $27.60 | |
| 86308 | <1% | 15 | $24.29 | |
| 87625 | <1% | 19 | $20.17 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 179 | $19.37 |
| 87102 | <1% | 42 | $16.90 | |
| 87206 | <1% | 42 | $16.90 | |
| 87116 | <1% | 42 | $16.90 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 27 | $14.42 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 291 | $14.22 |
| 96417 | <1% | 1,618 | $12.46 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 120 | $10.81 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 607 | $7.64 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 709 | $5.30 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 36 | $4.55 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 89 | $3.64 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 82 | $1.58 |
| 91305 | <1% | 45 | $0.35 | |
| J9190 | Injection, fluorouracil, 500 mg | 0% | 931 | $0.00 |
| H1000 | Prenatal care, at-risk assessment | 0% | 45 | $0.00 |
| 96401 | 0% | 29 | $0.00 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 94 | $0.00 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | 0% | 34 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 80 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 24 | $0.00 |
| 93356 | 0% | 16 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 19 | $0.00 |
| 92651 | 0% | 14 | $0.00 | |
| 00402 | 0% | 25 | $0.00 | |
| C1729 | Catheter, drainage | 0% | 15 | $0.00 |
| J9267 | Injection, paclitaxel, 1 mg | 0% | 736 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 207 | $0.00 |
| 96411 | 0% | 473 | $0.00 | |
| A4648 | Tissue marker, implantable, any type, each | 0% | 41 | $0.00 |
| 64494 | 0% | 21 | $0.00 | |
| 94761 | 0% | 166 | $0.00 | |
| 29540 | 0% | 27 | $0.00 | |
| J0173 | Injection, epinephrine (belcher), not therapeutically equivalent to j0171, 0.1 mg | 0% | 12 | $0.00 |
| 00160 | 0% | 13 | $0.00 | |
| 51798 | 0% | 23 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 25 | $0.00 |
| 00790 | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCROFTON, MICHAEL (VICE PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Bethesda Hospital INC | Cincinnati, OH | $57.06M |
| Hospice of Cincinnati Incorporated | Cincinnati, OH | $54.08M |
| Trihealth G LLC | Cincinnati, OH | $30.89M |
| Trihealth H LLC | Cincinnati, OH | $12.50M |
| Mccullough-Hyde Memorial Hospital, INC. | Oxford, OH | $4.51M |
| Trihealth U LLC | Cincinnati, OH | $209K |
| Trihealth HF LLC | Oxford, OH | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.